SS Innovations International Inc. (NASDAQ: SSII) is pursuing a strategy to make robotic surgery more accessible and affordable, according to a recent interview with founder, chairman and CEO Dr. Sudhir Srivastava on the Medsider podcast. Rather than competing directly with established robotic surgery platforms, the company aims to expand the market by reducing equipment costs and enhancing physician training, with artificial intelligence, automation, and new robotic platforms central to its long-term product roadmap.
The SSi Mantra system, the company's flagship surgical robot, was designed to lower the cost of robotic surgery while supporting multiple specialties, including cardiac surgery. Dr. Srivastava emphasized that affordability and accessibility remain core priorities as the company expands its surgical robotics platform globally. Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely.
SS Innovations has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries. The company is pursuing FDA and European regulatory approvals while expanding into additional international markets. For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results, and SS Innovations is positioning itself as a key player in democratizing robotic surgery.
Dr. Srivastava noted that the company's objective is to broaden access to hospitals and patients that have historically been unable to adopt robotic surgery due to high equipment costs and operating expenses. By focusing on lower-cost technology and remote surgical capabilities, SS Innovations aims to address a significant unmet need in global healthcare.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
